[ad_1]
Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by a loss of interest and pleasure in a pleasant environment. People are affected in different ways by major depression. Some people have trouble sleeping, feel restless and irritable, and have sudden weight loss. In addition, they may have other mental and physical symptoms such as fatigue, memory loss, feelings of hopelessness, body aches, headaches, and suicidal thoughts.
Major depressive disorder can affect people at any stage of life. In adults, major depressive disorders are more common in people aged 25 to 44 years. In a lifetime, major depression affects 10% – 25% of women and 5% – 12% of men.
Sample Request Report @ https://www.persistencemarketresearch.com/samples/4190
It It is estimated that 10% – 25% of people who develop a major depressive disorder have already been diagnosed of dysthymia (dysthymic disorder), a form of depression. Some people may suffer from dysthymia and major depressive disorder at the same time. The presence of both conditions at the same time is known as the double depression.
The development of major depressive disorder may be related to certain medical conditions. About 20% – 25% of people with cancer, diabetes, stroke, and myocardial infarction are likely to develop major depressive disorder.
The world market for major depressive disorders is categorized according to the different types of drugs used to treat this disease. condition. Based on the type of therapeutic drug, the report covers selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants and antipsychotics. The main brands of selective serotonin reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran) and Savella (Milnacipran) . Antidepressants, such as norepinephrine, specific serotonergic antidepressants, norepinephrine-dopamine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors and Brintellix (Vortioxetine), are commonly used to treat major depressive disorders. . The main brands of antipsychotics are Abilify (Aripiprazole) and Seroquel XR (Quetiapine).
In terms of geography, North America dominates the global market for major depressive disorders due to heightened awareness of various depression conditions in the region. The United States is the largest market for major depressive disorders in North America, followed by Canada. In Europe, Germany, France, the United Kingdom, Italy and Spain represent an important part of the market for major depressive disorders. This Asian market is expected to grow significantly over the next five years. This is due to various companies setting up manufacturing facilities in the area. In addition, heightened awareness of the various episodes of depression and the increase in the geriatric population is also driving the market growth in the region. India, China and Japan are expected to be the most dynamic major depressive disorder markets in Asia.
In recent times, the increased demand for therapeutic products for the treatment of this disease is a key factor in the global market for major depressive disorders. . Increased investments in R & D in the pharmaceutical sector and the introduction of innovative medicines have also fueled the growth of this market. The ongoing development of drugs with properties, such as improved safety and high compliance of patients, also support the growth of the global market for major depressive disorders. Therapies, such as biological therapy, meditation and physiotherapy, have tremendous potential to stimulate growth in this market.
However, stringent regulations imposed by various governments hinder the growth of the global market for major depressive disorders. In addition, patent expirations of some blockbuster drugs (drugs with annual sales of $ 1.0 million or more) and the risk of complications and side effects badociated with antidepressants have hindered market growth. The growing mergers and acquisitions of drug manufacturing companies and rapid product launches are some of the major trends in the global market for major depressive disorders.
The main companies operating in this market are H. Lundbeck A / S, Otsuka Pharmaceutical Co., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.
Application Report for TOC @ https: //www.persistencemarketresearch. com / toc / 4190
Views:
2
Source link
